Clinical Trials Logo
  1. Home
  2. Colon Adenocarcinoma
  3. NCT03015038

Study of the Immune Response in Colon Adenocarcinoma — IMCO  

Colon Adenocarcinoma Clinical Trial

Official title:
Etude de la réponse Immunitaire Dans l'adénocarcinome Colique

Clinical Trial Summary

Duration of each part of the study per patient: - Screening: From 1 to 4 weeks - Sampling period (blood and tissue): 1 day - Follow-up by patient: 60 months - Total study duration by patient: 84 months - Total inclusion duration: 24 months - Total Follow-up duration: 60 months - Total study duration: 84 months

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03015038
Study type Observational
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact
Status Active, not recruiting
Phase
Start date February 5, 2017
Completion date February 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT04003181 - The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon N/A
Active, not recruiting NCT04057274 - Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth N/A
Completed NCT02127359 - Whole-Exome Sequencing (WES) of Cancer Patients
Completed NCT00096278 - Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Phase 3
Active, not recruiting NCT02912559 - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Phase 3
Completed NCT02569723 - Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy N/A
Recruiting NCT05746195 - Optimization of Adaptive Text Messages for Cancer Survivors (OATS II) N/A
Active, not recruiting NCT03365882 - S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT02393755 - Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05710406 - Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Phase 2/Phase 3
Recruiting NCT06017141 - Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study Phase 2
Active, not recruiting NCT03436563 - M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Phase 1/Phase 2
Recruiting NCT05482516 - Evaluating Novel Therapies in ctDNA Positive GI Cancers Phase 3
Completed NCT02368886 - Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT02863107 - Young-Onset Colorectal Cancer
Active, not recruiting NCT04963283 - Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer Phase 2
Recruiting NCT06414304 - Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
Completed NCT05872334 - The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer Surgery N/A
Not yet recruiting NCT06426927 - PeLear CCC: Proyecto Latino Contra Cancer Colorectal N/A
Completed NCT03949777 - Validation of Aer-O-Scope Colonoscope System Cecal Intubation N/A